Celgene, Evotec sign discovery pact | Chemical & Engineering News
Volume 95 Issue 1 | p. 13 | Concentrates
Issue Date: January 2, 2017

Celgene, Evotec sign discovery pact

Department: Business
Keywords: neuroscience, Celgene, Evotec, Alzheimer’s

Celgene will pay Evotec $45 million up front as part of a broad pact to develop drugs for neurodegenerative diseases, including Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. In conjunction with Harvard University, Evotec has developed a drug screening platform based on induced pluripotent stem cells. The partners hope that screening small molecules against patient-derived cells will increase the chances of finding drug candidates.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment